| Dr Robin Ginger Allister, MD | |
|
1 Evergreen Dr, East Providence, RI 02914-1506 | |
| (401) 438-3250 | |
| Not Available |
| Full Name | Dr Robin Ginger Allister |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 13 Years |
| Location | 1 Evergreen Dr, East Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720374036 | NPI | - | NPPES |
| 3098722 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 16697 (New Hampshire) | Secondary |
| 208M00000X | Hospitalist | MD17249 (Rhode Island) | Secondary |
| 207R00000X | Internal Medicine | MD17249 (Rhode Island) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| South County Nursing & Rehabilitation Center | North kingstown, RI | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Blueprint Healthcare Llc | 1153665062 | 16 |
News Archive
The contract with Verizon Communications Inc.'s Terremark subsidiary, which hosts healthcare.gov, had been set to expire March 30, the day before the end of open enrollment.
The University of Maryland School of Medicine has been awarded a three-year, $2.47 million grant from the National Institute of Allergy and Infectious Diseases to develop a vaccine to protect against Shigella and Enterotoxigenic Escherichia coli (ETEC), pathogens which are among the leading causes of diarrheal diseases in young children in developing countries and a common cause of "traveler's diarrhea" among travelers to these countries.
A Cedars-Sinai Heart Institute physician researcher has received a $2.5 million grant from the National Heart, Lung, and Blood Institute to develop a risk assessment tool that could identify patients susceptible to sudden cardiac arrest, a usually fatal heart rhythm malfunction.
Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.
A new discovery about how the body transports dexamethasone, a drug that can increase the survival chances of patients with severe COVID-19, suggests diabetes and other factors may reduce its potentially lifesaving effectiveness.
› Verified 2 days ago
| Entity Name | Lifespan Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407116643 PECOS PAC ID: 2567455082 Enrollment ID: O20121029000368 |
News Archive
The contract with Verizon Communications Inc.'s Terremark subsidiary, which hosts healthcare.gov, had been set to expire March 30, the day before the end of open enrollment.
The University of Maryland School of Medicine has been awarded a three-year, $2.47 million grant from the National Institute of Allergy and Infectious Diseases to develop a vaccine to protect against Shigella and Enterotoxigenic Escherichia coli (ETEC), pathogens which are among the leading causes of diarrheal diseases in young children in developing countries and a common cause of "traveler's diarrhea" among travelers to these countries.
A Cedars-Sinai Heart Institute physician researcher has received a $2.5 million grant from the National Heart, Lung, and Blood Institute to develop a risk assessment tool that could identify patients susceptible to sudden cardiac arrest, a usually fatal heart rhythm malfunction.
Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.
A new discovery about how the body transports dexamethasone, a drug that can increase the survival chances of patients with severe COVID-19, suggests diabetes and other factors may reduce its potentially lifesaving effectiveness.
› Verified 2 days ago
| Entity Name | Rhode Island Post Acute Medical Services 1 Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134658966 PECOS PAC ID: 9133493786 Enrollment ID: O20170920000893 |
News Archive
The contract with Verizon Communications Inc.'s Terremark subsidiary, which hosts healthcare.gov, had been set to expire March 30, the day before the end of open enrollment.
The University of Maryland School of Medicine has been awarded a three-year, $2.47 million grant from the National Institute of Allergy and Infectious Diseases to develop a vaccine to protect against Shigella and Enterotoxigenic Escherichia coli (ETEC), pathogens which are among the leading causes of diarrheal diseases in young children in developing countries and a common cause of "traveler's diarrhea" among travelers to these countries.
A Cedars-Sinai Heart Institute physician researcher has received a $2.5 million grant from the National Heart, Lung, and Blood Institute to develop a risk assessment tool that could identify patients susceptible to sudden cardiac arrest, a usually fatal heart rhythm malfunction.
Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.
A new discovery about how the body transports dexamethasone, a drug that can increase the survival chances of patients with severe COVID-19, suggests diabetes and other factors may reduce its potentially lifesaving effectiveness.
› Verified 2 days ago
| Entity Name | Blueprint Healthcare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467927483 PECOS PAC ID: 1153665062 Enrollment ID: O20200626000337 |
News Archive
The contract with Verizon Communications Inc.'s Terremark subsidiary, which hosts healthcare.gov, had been set to expire March 30, the day before the end of open enrollment.
The University of Maryland School of Medicine has been awarded a three-year, $2.47 million grant from the National Institute of Allergy and Infectious Diseases to develop a vaccine to protect against Shigella and Enterotoxigenic Escherichia coli (ETEC), pathogens which are among the leading causes of diarrheal diseases in young children in developing countries and a common cause of "traveler's diarrhea" among travelers to these countries.
A Cedars-Sinai Heart Institute physician researcher has received a $2.5 million grant from the National Heart, Lung, and Blood Institute to develop a risk assessment tool that could identify patients susceptible to sudden cardiac arrest, a usually fatal heart rhythm malfunction.
Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.
A new discovery about how the body transports dexamethasone, a drug that can increase the survival chances of patients with severe COVID-19, suggests diabetes and other factors may reduce its potentially lifesaving effectiveness.
› Verified 2 days ago
| Entity Name | West Coast Health And Rehab Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043743891 PECOS PAC ID: 8325315609 Enrollment ID: O20201218000804 |
News Archive
The contract with Verizon Communications Inc.'s Terremark subsidiary, which hosts healthcare.gov, had been set to expire March 30, the day before the end of open enrollment.
The University of Maryland School of Medicine has been awarded a three-year, $2.47 million grant from the National Institute of Allergy and Infectious Diseases to develop a vaccine to protect against Shigella and Enterotoxigenic Escherichia coli (ETEC), pathogens which are among the leading causes of diarrheal diseases in young children in developing countries and a common cause of "traveler's diarrhea" among travelers to these countries.
A Cedars-Sinai Heart Institute physician researcher has received a $2.5 million grant from the National Heart, Lung, and Blood Institute to develop a risk assessment tool that could identify patients susceptible to sudden cardiac arrest, a usually fatal heart rhythm malfunction.
Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.
A new discovery about how the body transports dexamethasone, a drug that can increase the survival chances of patients with severe COVID-19, suggests diabetes and other factors may reduce its potentially lifesaving effectiveness.
› Verified 2 days ago
| Entity Name | Nv Pacs 2 Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427534809 PECOS PAC ID: 0941550578 Enrollment ID: O20211001000134 |
News Archive
The contract with Verizon Communications Inc.'s Terremark subsidiary, which hosts healthcare.gov, had been set to expire March 30, the day before the end of open enrollment.
The University of Maryland School of Medicine has been awarded a three-year, $2.47 million grant from the National Institute of Allergy and Infectious Diseases to develop a vaccine to protect against Shigella and Enterotoxigenic Escherichia coli (ETEC), pathogens which are among the leading causes of diarrheal diseases in young children in developing countries and a common cause of "traveler's diarrhea" among travelers to these countries.
A Cedars-Sinai Heart Institute physician researcher has received a $2.5 million grant from the National Heart, Lung, and Blood Institute to develop a risk assessment tool that could identify patients susceptible to sudden cardiac arrest, a usually fatal heart rhythm malfunction.
Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.
A new discovery about how the body transports dexamethasone, a drug that can increase the survival chances of patients with severe COVID-19, suggests diabetes and other factors may reduce its potentially lifesaving effectiveness.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Robin Ginger Allister, MD Po Box 655, Exeter, NH 03833-0655 Ph: () - | Dr Robin Ginger Allister, MD 1 Evergreen Dr, East Providence, RI 02914-1506 Ph: (401) 438-3250 |
News Archive
The contract with Verizon Communications Inc.'s Terremark subsidiary, which hosts healthcare.gov, had been set to expire March 30, the day before the end of open enrollment.
The University of Maryland School of Medicine has been awarded a three-year, $2.47 million grant from the National Institute of Allergy and Infectious Diseases to develop a vaccine to protect against Shigella and Enterotoxigenic Escherichia coli (ETEC), pathogens which are among the leading causes of diarrheal diseases in young children in developing countries and a common cause of "traveler's diarrhea" among travelers to these countries.
A Cedars-Sinai Heart Institute physician researcher has received a $2.5 million grant from the National Heart, Lung, and Blood Institute to develop a risk assessment tool that could identify patients susceptible to sudden cardiac arrest, a usually fatal heart rhythm malfunction.
Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.
A new discovery about how the body transports dexamethasone, a drug that can increase the survival chances of patients with severe COVID-19, suggests diabetes and other factors may reduce its potentially lifesaving effectiveness.
› Verified 2 days ago
Matthew J Franco, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 900 Warren Ave, Suite 401, East Providence, RI 02914 Phone: 800-508-4908 Fax: 401-228-6236 | |
Mr. Michael F Gilson, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 950 Warren Ave, 2nd Floor, East Providence, RI 02914 Phone: 401-606-1004 Fax: 401-606-1153 | |
Dr. Christopher Song, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 950 Warren Ave, East Providence, RI 02914 Phone: 401-606-1004 Fax: 401-606-1153 | |
Dr. Ricardo Rafael Correa Marquez, M.D Internal Medicine Medicare: Medicare Enrolled Practice Location: 900 Warren Avenue, Suite 300, East Providence, RI 02914 Phone: 786-246-5719 | |
May Min, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 950 Warren Ave Ste 301, East Providence, RI 02914 Phone: 401-606-4260 | |
Prerna Ganjoo, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 318 Waterman Ave, East Providence, RI 02914 Phone: 401-438-5950 Fax: 401-435-6700 | |
Mordecai Jeremiah Stolk, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 318 Waterman Ave, East Providence, RI 02914 Phone: 401-438-5950 Fax: 401-435-6700 |